11194 RESULTS
COMMENT The original paper on the App-SAA knock-in mouse model of Alzheimer’s disease (JAX: 034711) reported that FDG-PET uptake, a surrogate for glucose utilization in brain, revealed cortical hypermetabolism across the studied lifespan of 5-20 months in homozyg
COMMENT A word of caution for those who are trying to extract biological meaning from tau RD biosensor cell lines: Nuclear tau aggregates are an artifact of the truncation used in the model. Disease-relevant full-length tau aggregates never localize to the nucleu
COMMENT In Parkinson’s as in Alzheimer’s disease, biological markers are important to improve early diagnostics. This paper provides strong evidence that cutaneous phosphorylated α-synuclein may serve as diagnostic biomarker for Parkinson’s disease (PD), dementia
COMMENT This study confirms previous smaller studies showing that the levels of phosphorylated α-synuclein are increased in peripheral nerve terminals in the skin in neurological diseases characterized by accumulation of α-synuclein aggregates in the brain. The s
COMMENT In this comprehensive work by the de Jager team, the authors addressed the effects of genetic variants on cell type- and cell subtype-specific gene expression in human brains. Using a large number of human brains and a wealth of genetic and new single-nuc
COMMENT Divide and Conquer: Compartmentalization of the Brain’s Subarachnoid Space Facilitates Rapid Periarterial CSF Flow Over the past decade, there has been significant interest in comprehending the underlying anatomy and physiological mechanisms that regulate
COMMENT This is an exciting study—it provides the first view into tracer movement through the human subarachnoid space over just a few hours. They find that tracers move in a specific pathway along the arteries before entering brain tissue. This information is im
COMMENT This may have been the fourth randomized Phase 3 trial of a form of methylene blue in various doses by this company. None was statistically significant compared to their contemporaneous controls. The trials used a small dose of HMTM or similar as the cont
COMMENT The saga of “methylene blue,” or derivatives of this dye with various names, including LMT-X/LMTM and HMTM, continues with a presentation of TauRx-sponsored work at ADPD 2024. The history of this drug, which putatively targets tau aggregation at low doses
COMMENT Firstly, I think these results are fantastic and show the possibilities of BBB-crossing immunotherapy. The big question I would have thought is, have the patients been cured? Moreover, or alternatively, if the patients had been treated in their 20s, 30s,
COMMENT The paper by Wilson et al. is extremely timely and important. It attributes a key role to myeloid cells in coping with aging in general, and age-related neurodegenerative diseases in particular, with an emphasis on Alzheimer’s disease, focusing on trigger
COMMENT This paper highlights, and raises questions about, potential crosstalk between the peripheral immune system and central nervous system microglia and how this communication could be a powerful modulator of neurodegeneration. While the authors found very sm
COMMENT Fantastic work by both groups. The work by Jonathan Kipnis and colleagues could provide an additional explanation for why we saw plaque clearance in APP/PS1 mice after optogenetic rescue of slow waves during sleep. kkastanenka_305846 0 Sleep restoration b
COMMENT This is an interesting paper, even though it is not directed toward Alzheimer’s disease. It does make some fundamental observations that are worth noting, and which are pertinent to Alzheimer’s. One is that mitochondrial function influences the activity a
COMMENT We have read the study from Milioto et al. with much interest, because last year we published a clinical study in which we made a similar observation (Gogishvili et al., 2023), namely that while TGF-β1 was increased in dementia compared to controls, it wa
